Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECTED: High-dose clopidogrel pretreatment for reduction of thrombotic events after elective drug-eluting stent PCI
2004-000517-19Phase 4Unknown
- Sponsor
- Blackpool Teaching Hospitals NHS Foundation Trust
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of clopidogrel in coronary arteriosclerosis and cardiac ischemia, sponsored by Blackpool Teaching Hospitals NHS Foundation Trust. Primary endpoints: Inhibition of platelet aggregation and Thrombosis-related ischemic events. Status: unknown.
02
Drugs
clopidogrel
03
Conditions
coronary arteriosclerosiscardiac ischemia
Beyond the preview
Go deeper on 2004-000517-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000517-19.